The antibody drug conjugate MORAb2, consisting of farletuzumab paired with a cathepsin Bヽleavable linker and eribulin, targets folate receptor alpha (FRA), which is frequently overexpressed on various tumor types. MORAb2 was highly cytotoxic to FRA﹑ositive cells in vitro, with limited off‐...
however, treatment using mAbs alone is often insufficient, potentially due to less satisfactory lethality against cancer cells compared to chemotherapy.17Hence, a novel concept, known as antibody–drug conjugate (ADC), was conceived to bridge the gap between the mAb and ...
以enfortumab vedotin (EV)为例,EV是靶向Nectin-4的ADC,payload是微管抑制剂 MMAE。2023年ESMO报道的EV-302研究,EV联合帕博利珠单抗1线治疗晚期尿路上皮癌相较于含铂化疗的中位总生存期(OS)分别为 31.5个月和16.1个月,取得了生存期获益的显著阳性结果,亚组分析数据提示,无论是否耐受顺铂、PD-L1表达和肝转移存...
Omotola D.Ogundipe, ...Simeon K.Adesina, inBiomedicine & Pharmacotherapy, 2023 2Antibody-drug conjugates (ADCs) An antibody-drug conjugate (ADC) is adrug conjugatesystem comprising acytotoxic agentwhich is conjugated through a linker with an antibody that targets specific tumor-associated antige...
Antibody–drug conjugates (ADCs) have become a key therapeutic modality in oncology, spurred by superior clinical profiles compared to standard-of-care chemotherapy across multiple indications. Consequently, revenue from approved ADCs and those in phase III development is forecasted to reach $26 billion...
Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that the Company presented data characterizing the preclinical profile of its EpCAM-targeting ADC, CX-2051, at the World ADC conferen...
摩根士丹利在最近的一份研究报告中表示,个体化癌症疫苗和抗体药物偶联物(antibody-drug conjugate,ADC)将成为明年主要的癌症治疗生物技术创新之一,包括 Moderna (MRNA.US)、 默沙东 (MRK.US)和 阿斯利康 (AZ... 网页链接
PURPOSE :MORAb-202, an antibody-drug conjugate containing farletuzumab and eribulin with a cathepsin-B cleavable linker, targets folate receptor 伪 (FR伪)-expressing tumor cells. The primary objective of this first-in-human study was to ... T Shimizu,Y Fujiwara,Y Kan,... - 《Clinical Can...
Multivalent protein-drug conjugates – An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells 2023, Biotechnology Advances Citation Excerpt : PDC based on Cupid and Psyche can either be pre-assembled, yielding a tetravalent PDC with specificity determined by scF...
Zhang, J. et al. Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours.NPJ Breast Cancer9, 28 (2023). ArticleCASPubMedPubMed CentralGoogle Scholar Zhu, Y., Liu, K., Wang, K. & Zhu, H. Treatment-related adverse events of antibody-drug conjuga...